Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years

Background To evaluate the association of statins and co‐morbidities with new onset type 2 diabetes mellitus (T2DM) in patients 65 years and older. Methods This retrospective study used de‐identified administrative healthcare claims and enrolment data from a Medicare Advantage Prescription Drug (MAP...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes/metabolism research and reviews 2020-09, Vol.36 (6), p.e3310-n/a
Main Authors: Tangelloju, Srikanth, Little, Bert B., Esterhay, Robert J., Brock, Guy, LaJoie, Scott
Format: Article
Language:English
Subjects:
Age of Onset
Aged
Comorbidity
diabetes
Diabetes Mellitus, Type 2 - chemically induced
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - epidemiology
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Incidence
Male
Medicare
onset
Prognosis
propensity
retrospective
Retrospective Studies
statin
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background To evaluate the association of statins and co‐morbidities with new onset type 2 diabetes mellitus (T2DM) in patients 65 years and older. Methods This retrospective study used de‐identified administrative healthcare claims and enrolment data from a Medicare Advantage Prescription Drug (MAPD) health plan offered by a large multistate healthcare company. The plan covered >2.4 million individuals, of whom >1.7 million individuals were ≥65 years. Of these, 265 554 individuals had continuous MAPD enrolment January 2008 to December 2015. The unadjusted model assessed demographic, pharmacy and T2DM co‐morbidities as covariates. Significant variables (P 
ISSN:1520-7552
1520-7560
DOI:10.1002/dmrr.3310